The FDA has released a batch of letters highlighting their initial concerns about certain new drugs—most of which were already publicly available. While these drugs eventually got the green light, the letters show the regulatory hurdles they faced early on, with FDA Commissioner Dr. Marty Makary involved in the process.

Editor’s Note: This isn’t a scandal—it’s more like a behind-the-scenes look at how the FDA scrutinizes new meds before approval. The fact that these drugs eventually passed suggests the system works, but it’s still interesting to see where regulators drew the line. For patients and investors, it’s a reminder that even successful drugs face tough questions first.